PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease

Sickle Cell Disease Clinical Trial

Official title:

Phase 1 Pharmacokinetic and Pharmacodynamic Responses to Oral L-Citrulline in Patients With Sickle Cell Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT00343954
• Other study ID #: ANGX-3227-01
• Status: Not yet recruiting
• Phase: Phase 1
• First received: June 21, 2006
• Last updated: June 21, 2006

Study information

• Verified date: June 2006
• Source: Angiogenix
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To evaluate PK and PD responses to L-citrulline given orally for four weeks to patients with sickle cell disease who are otherwise healthy.

Description:

Phase 1, single center, open label, multiple-dose study consisting of a screening period followed by four weeks of treatment. At least 12 male and female patients, 10 years of age or older, with sickle cell disease but otherwise healthy, will be enrolled in the study.

PK measurements include plasma concentrations of L-citrulline, L-arginine, L-ornithine, and L-proline following the first dose of orally administered L-citrulline and after four weeks of twice daily administration of the drug.

PD measurements include intercellular and vascular adhesion molecules (ICAM, VCAM, and E-selectin), surrogate markers of sickle cell disease activity, and PAT, a measurement of vascular function.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 12
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 10 Years and older

Eligibility

Inclusion Criteria:

1. Male or female, 10 years of age or older on the day of dosing, and generally healthy as determined by medical history, physical examination, and laboratory test values

2. Diagnosis of sickle cell anemia (Hb SS)

3. For female of child-bearing potential, a negative serum pregnancy test and using an adequate method of contraception

4. Has signed and received a copy of the written informed consent form approved by the investigator’s Institutional Review Board (IRB), understands the purposes and risks of the study and agrees to follow the restrictions and schedule of procedures as defined by this protocol

Exclusion Criteria:

1. History of sickle-cell–related pain crisis within two weeks of study

2. Pregnant or breast feeding

3. Transfusion within last 90 days

4. Creatinine >1.5 X upper limit of normal

5. SGPT > 2 X upper limit of normal

6. History of allergic reaction to arginine or citrulline product

7. Requires chronic medication other than study drug that cannot be discontinued during the study period

8. Unable to take or tolerate oral medications

9. Unreliable venous access

10. Noncompliant with regular care

11. Participation in an investigational drug or medical device study within previous 30 days

12. In the opinion of the investigator is not a good candidate for participation in the study

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease

Intervention

Drug:
• L-citrulline tablets, 1000 mg

Locations

Country	Name	City	State
United States	Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center Health System	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Angiogenix

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PK and PD responses to L-citrulline
Primary	Endpoints will be determined as change from baseline
Secondary	Assessment of safety and tolerability of L-citrulline,